Back in April, Dr. Chaplin made a prediction about a pancreatic cancer drug on this channel. On the 26th of August, it came true — and faster than even he expected.
In this episode, you'll learn:
The one detail on the label that reaches far more patients than earlier drugs like it
A piece of online misinformation about this approval — and where it goes too far
Why it cleared the FDA six and a half months early, and what that says about the data
What happens now for patients who were getting it through expanded access
Three questions worth bringing to your next oncology appointment
If pancreatic cancer touches your life — or you're watching this space because of how RAS-driven cancers behave more broadly — this is the episode to watch first.
Disclaimer: The information provided in this podcast is for educational and informational purposes only, and does not constitute medical advice. It is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition. Never disregard professional medical advice or delay in seeking it because of something you have heard or read in this podcast or on this channel. Reliance on any information provided by Dr. Jay Chaplin or Elevating Cancer Treatment is solely at your own risk. Dr. Jay Chaplin is a scientist and drug developer, not a medical doctor providing patient care. The content presented here reflects general scientific understanding and research, and may not be applicable to your individual health circumstances. Individual medical conditions and treatments vary, and no two situations are exactly alike. Always consult with your personal healthcare provider before making any decisions about your health or treatment plan.
Podden och tillhörande omslagsbild på den här sidan tillhör
Dr. Jay Chaplin. Innehållet i podden är skapat av Dr. Jay Chaplin och inte av,
eller tillsammans med, Poddtoppen.
